PULSE BIOSCIENCES, INC. 8-K

What Happened
Pulse Biosciences, Inc. (PLSE) filed an 8-K on March 9, 2026 to announce long-term follow-up results from its first‑in‑human feasibility study of the nPulse™ Vybrance™ Percutaneous Electrode System. The data were presented March 6, 2026 at the North American Society for Interventional Thyroidology meeting by Prof. Stefano Spiezia (Ospedale del Mare), and cover a subset of 21 patients followed for 15–22 months after treatment of benign thyroid nodules using nsPFA energy.

Key Details

• Average 74% reduction in treated benign thyroid nodule volume at 15–22 months.
• Continued volume reduction observed from 1 month through 22 months; no nodule regrowth reported at 15–22 months.
• Patient satisfaction: 100% reported “Highly Satisfied” for cosmetic outcome; 95% “Highly Satisfied” for overall satisfaction at final follow-up.
• Safety: no serious adverse events reported and no intranodular fibrosis detected on ultrasounds at 15–22 months.

Why It Matters
These results highlight potential long‑term durability and a favorable safety/tolerability profile for Pulse’s nPulse Vybrance system in treating benign thyroid nodules—key considerations for clinicians, patients, and investors evaluating the clinical and commercial potential of the technology. The company attached the press release summarizing these findings as Exhibit 99.1 to the 8‑K.